Product Information

EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $88.7879 per EA under NDC 00378544093. Its NADAC has been published 39 times since Feb 18, 2026.

FDA first approved this application on May 20, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB

Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate
$88.7879per EA

Strength

200; 25; 300 mg/1; mg/1; mg/1

NDC

00378544093

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208452

FDA Approved

5/20/2025

TE Code

AB

On Market Since

5/27/2025

Price Statistics

The NADAC for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB has been published 39 times since Feb 18, 2026, and over the history we have for it it has declined 22.7%. The table below summarizes its recorded NADAC range and movement.

Current price$88.7879 per EA
All-time high$114.9924 (Jul 15, 2026)
All-time low$88.7879 (Oct 21, 2026)
52-week high$114.9924
52-week low$88.7879
Median price$114.8597
Average price$112.1293
Largest weekly change-22.5% (Oct 21, 2026)
Weeks tracked39
Tracking sinceFeb 18, 2026

Price History

1W

0.0%

1M

-22.5%

3M

-22.6%

6M

-22.8%

1Y

N/A

3Y

N/A

5Y

N/A

All

-22.7%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB, manufactured by Mylan Pharmaceuticals Inc., is $88.7879 per EA (NDC 00378544093), effective Nov 11, 2026.

How has the price of EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB changed over time?

Over the history we have for it, the NADAC for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB has declined 22.7%. It has been tracked across 39 weekly CMS publications since Feb 18, 2026.

What are the highest and lowest recorded NADAC prices for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?

Since Feb 18, 2026, the NADAC for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB has ranged from a low of $88.7879 (Oct 21, 2026) to a high of $114.9924 (Jul 15, 2026), with a median of $114.8597 per EA.

Are there cheaper alternatives to EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?

No other NADAC-published product currently shares the active ingredient and strength of EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?

EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB (NDC 00378544093) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.